Embryonic cardiac arrhythmia and generation of reactive oxygen species: Common teratogenic mechanism for IKr blocking drugs

Reproductive Toxicology

Volumn 24, Issue 1, 2007, Pages 42-56

  Danielsson, Bengt R ^a   Danielsson, Christian ^b   Nilsson, Mats F ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Embryonic arrhythmia; hERG; Hypoxia; IKr blocking drugs; Malformation; Reactive oxygen species

Indexed keywords

1' [2 (BENZOFURAZAN 5 YL)ETHYL] 3,4 DIHYDRO 6 METHANESULFONAMIDOSPIRO[2H 1 BENZOPYRAN 2,4' PIPERIDIN] 4 ONE; ALMOKALANT; ANTIARRHYTHMIC AGENT; ASTEMIZOLE; CETIRIZINE; CISAPRIDE; DELAYED RECTIFIER POTASSIUM CHANNEL; DIMETHADIONE; DOFETILIDE; IBUTILIDE; MOSAPRIDE CITRATE; PHENYTOIN; POTASSIUM CHANNEL BLOCKING AGENT; REACTIVE OXYGEN METABOLITE; SCAVENGER; TRIMETHADIONE;

AGENESIS; ASYSTOLE; BRADYCARDIA; CLEFT FACE; CLEFT LIP; CONGENITAL BLOOD VESSEL MALFORMATION; CONGENITAL MALFORMATION; DISTAL DIGITAL REDUCTION; DRUG EFFECT; DRUG FATALITY; DRUG MECHANISM; DRUG MEGADOSE; EMBRYO DEATH; EMBRYONIC CARDIAC ARRHYTHMIA; EMBRYOTOXICITY; FETAL HYDANTOIN SYNDROME; FINGER MALFORMATION; GREAT VESSELS TRANSPOSITION; GROWTH RETARDATION; HEART ARRHYTHMIA; HEART SEPTUM DEFECT; HUMAN; HYPOXIA; NONHUMAN; OXYGEN SUPPLY; PATHOPHYSIOLOGY; REOXYGENATION; REVIEW; RISK FACTOR; SIDE EFFECT; SINGLE DRUG DOSE; SUDDEN DEATH; TERATOGENICITY; UROGENITAL TRACT MALFORMATION;

ABNORMALITIES, DRUG-INDUCED; ANIMALS; ANOXIA; ANTI-ARRHYTHMIA AGENTS; ANTICONVULSANTS; ARRHYTHMIA; ASTEMIZOLE; CISAPRIDE; DIMETHADIONE; ETHER-A-GO-GO POTASSIUM CHANNELS; FEMALE; FREE RADICAL SCAVENGERS; GASTROINTESTINAL AGENTS; HEART; HISTAMINE ANTAGONISTS; HUMANS; PHENYTOIN; POTASSIUM CHANNEL BLOCKERS; PREGNANCY; REACTIVE OXYGEN SPECIES; TERATOLOGY; TOXICITY TESTS;

EID: 34447262150     PISSN: 08906238     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.reprotox.2007.04.005     Document Type: Review

References (91)

1. Lefer D.J., and Granger D.N. Oxidative stress and cardiac disease. Am J Med 109 (2000) 315-323
2. Grabowski C. Embryonic oxygen deficiency-a physiological approach to analysis of teratological mechanisms. In: Woollam D.H.M. (Ed). Advances in Teratology (1970), Logos Press Ltd., London 125-169
3. Brent R.L., and Franklin J.B. Uterine vascular clamping: new procedure for the study of congenital malformations. Science 132 (1960) 89-91
4. Curley F.J., and Ingalls T.H. Hypoxia at normal atmospheric pressure as a cause of congenital malformations in mice. Proc Soc Exp Biol Med 94 (1957) 87-88
5. Franklin J.B., and Brent R.L. The effect of uterine vascular clamping on the development of rat embryos 3-14 days old. J Morphol 115 (1964) 273-290
6. Leist K.H., and Grauwiler J. Influence of the developmental stage on embryotoxicity following uterine vessel clamping in the rat. European Teratology Society: 2nd Conference (1973) 173-176
7. Leist K.H., and Grauwiler J. Fetal pathology in rats following uterine-vessel clamping on day 14 of gestation. Teratology 10 (1974) 55-67
8. Webster W.S., Lipson A.H., and Brown-Woodman P.D. Uterine trauma and limb defects. Teratology 35 (1987) 253-260
9. Degenhardt K. Analysis of intra-uterine malformations of the vertebral column induced by oxygen deficiency in rabbits. Proc Xth Int Cong of Genetics 2 (1958) 66-67
10. Ingalls T.H., and Curley F.J. Principles governing the genesis of congenital malformations induced in mice by hypoxia. N Engl J Med 257 (1957) 1121-1127
11. Morawa A.P., and Han S.S. Studies on hypoxia. I. Gross and histologic influences of maternal anoxia upon the developing rat foetus. Arch Oral Biol 13 (1968) 745-754
12. Murakami M., and Kameyama Y. Vertebral malformation in the foetus caused by maternal hypoxia during early stages of pregnancy. J Embryol Exp Morph 11 (1963) 107-118
13. Bronsky P.T., Johnston M.C., and Sulik K.K. Morphogenesis of hypoxia-induced cleft lip in CL/Fr mice. J Craniofac Genet Dev Biol Suppl 2 (1986) 113-128
14. Naujoks H. Effect of short-term oxygen deficiency on development of chick embryo in the first five days of incubation. Beitr Pathol Anat 113 (1953) 221-252
15. Li C., and Jackson R.M. Reactive species mechanisms of cellular hypoxia-reoxygenation injury. Am J Physiol Cell Physiol 282 (2002) C227-C241
16. Fantel A.G., Barber C.V., Carda M.B., Tumbic R.W., and Mackler B. Studies of the role of ischemia/reperfusion and superoxide anion radical production in the teratogenicity of cocaine. Teratology 46 (1992) 293-300
17. Fantel A.G., Person R.E., Tumbic R.W., Nguyen T.D., and Mackler B. Studies of mitochondria in oxidative embryotoxicity. Teratology 52 (1995) 190-195
18. Fantel A.G., and Person R.E. Involvement of mitochondria and other free radical sources in normal and abnormal fetal development. Ann N Y Acad Sci 959 (2002) 424-433
19. Maulik D., Numagami Y., Ohnishi S.T., Mishra O.P., and Delivoria-Papadopoulos M. Direct measurement of oxygen free radicals during in utero hypoxia in the fetal guinea pig brain. Brain Res 798 (1998) 166-172
20. Becker L.B. New concepts in reactive oxygen species and cardiovascular reperfusion physiology. Cardiovasc Res 61 (2004) 461-470
21. Colatsky T.J., and Argentieri T.M. Potassium channel blockers as antiarrhythmic drugs. Drug Dev Res 33 (1994) 235-249
22. Abrahamsson C., Palmer M., Ljung B., et al. Induction of rhythm abnormalities in the fetal rat heart. A tentative mechanism for the embryotoxic effect of the class III antiarrhythmic agent almokalant. Cardiovasc Res 28 (1994) 337-344
23. Abrahamsson C. Proarrhythmias related to delayed repolarisation. Importance of dispertion of repolarisation and early afterpolarisations (1996), Vasastadens Bokbinderi AB, Göteborg
24. Carlsson L., Abrahamsson C., Andersson B., Duker G., and Schiller-Linhardt G. Proarrhythmic effects of the class III agent almokalant: importance of infusion rate, QT dispersion, and early after depolarizations. Cardiovasc Res 27 (1993) 2186-2193
25. + current in cardiac myocytes by dofetilide. J Pharmacol Exp Ther 262 (1992) 809-817
26. Brouillette J., Lupien M.A., St-Michel C., and Fiset C. Characterization of ventricular repolarisation in male and female guinea pigs. J Mol Cell Cardiol 42 (2007) 357-366
27. + current in human ventricular myocytes. Circ Res 78 (1996) 689-696
28. + channels in mouse heart. Circ Res 79 (1996) 79-85
29. Langheinrich U., Vacun G., and Wagner T. Zebrafish embryos express an orthologue of hERG and are sensitive toward a range of QT-prolonging drugs inducing severe arrhythmia. Toxicol Appl Pharmacol 193 (2003) 370-382
30. Krogh-Madsen T., Schaffer P., Skriver A.D., et al. An ionic model for rhythmic activity in small clusters of embryonic chick ventricular cells. Am J Physiol Heart Circ Physiol 289 (2005) H398-H413
31. Davies M.P., An R.H., Doevendans P., Kubalak S., Chien K.R., and Kass R.S. Developmental changes in ionic channel activity in the embryonic murine heart. Circ Res 78 (1996) 15-25
32. Chun K.R., Koenen M., Katus H.A., and Zehelein J. Expression of the IKr components KCNH2 (rERG) and KCNE2 (rMiRP1) during late rat heart development. Exp Mol Med 36 (2004) 367-371
33. He J.Q., Ma Y., Lee Y., Thomson J.A., and Kamp T.J. Human embryonic stem cells develop into multiple types of cardiac myocytes: action potential characterization. Circ Res 93 (2003) 32-39
34. Franco D., Demolombe S., Kupershmidt S., et al. Divergent expression of delayed rectifier K(+) channel subunits during mouse heart development. Cardiovasc Res 52 (2001) 65-75
35. Webster W.S., Brown-Woodman P.D., Snow M.D., and Danielsson B.R. Teratogenic potential of almokalant, dofetilide, and d-sotalol: drugs with potassium channel blocking activity. Teratology 53 (1996) 168-175
36. Ban Y., Konishi R., Kawana K., Nakatsuka T., Fujii T., and Manson J.M. Embryotoxic effects of L-691,121, a class III antiarrhythmic agent, in rats. Arch Toxicol 69 (1994) 65-71
37. Spence S.G., Vetter C., and Hoe C.M. Effects of the class III antiarrhythmic, dofetilide (UK-68,798) on the heart rate of midgestation rat embryos, in vitro. Teratology 49 (1994) 282-292
38. Danielsson B.R. Malformations and fetal hypoxia induced by exaggerated pharmacological effects. In: Sundwall A., Danielsson B.R., Hagberg O., Lindgren E., Sjöberg P., and Viktor A. (Eds). Developmental toxicology preclinical and clinical data in retrospect (1993), Tryckgruppen, Stockholm 45-52
39. Marks T.A., and Terry R.D. Developmental toxicity of ibutilide fumarate in rats after oral administration. Teratology 54 (1996) 157-164
40. Wellfelt K., Skold A.C., Wallin A., and Danielsson B.R. Teratogenicity of the class III antiarrhythmic drug almokalant. Role of hypoxia and reactive oxygen species. Reprod Toxicol 13 (1999) 93-101
41. Skold A.C., Wellfelt K., and Danielsson B.R. Stage-specific skeletal and visceral defects of the I(Kr)-blocker almokalant: further evidence for teratogenicity via a hypoxia-related mechanism. Teratology 64 (2001) 292-300
42. Skold A.C., and Danielsson B.R. Developmental toxicity of the class III antiarrhythmic agent almokalant in mice. Adverse effects mediated via induction of embryonic heart rhythm abnormalities. Arzneimittelforschung 50 (2000) 520-525
43. Ingalls T.H., Curley F.J., and Prindle R.A. Experimental production of congenital anomalies; timing and degree of anoxia as factors causing fetal deaths and congenital anomalies in the mouse. N Engl J Med 247 (1952) 758-768
44. Lee Y.M., Jeong C.H., Koo S.Y., et al. Determination of hypoxic region by hypoxia marker in developing mouse embryos in vivo: a possible signal for vessel development. Dev Dyn 220 (2001) 175-186
45. Danielsson B.R., Skold A.C., Johansson A., Dillner B., and Blomgren B. Teratogenicity by the hERG potassium channel blocking drug almokalant: use of hypoxia marker gives evidence for a hypoxia-related mechanism mediated via embryonic arrhythmia. Toxicol Appl Pharmacol 193 (2003) 168-176
46. Zimmerman E.F., Potturi R.B., Resnick E., and Fisher J.E. Role of oxygen free radicals in cocaine-induced vascular disruption in mice. Teratology 49 (1994) 192-201
47. Fantel A.G. Reactive oxygen species in developmental toxicity: review and hypothesis. Teratology 53 (1996) 196-217
48. Fantel A.G., Stamps L.D., Tran T.T., Mackler B., Person R.E., and Nekahi N. Role of free radicals in the limb teratogenicity of L-NAME (N(G)-nitro-(l)-arginine methyl ester): a new mechanistic model of vascular disruption. Teratology 60 (1999) 151-160
49. Rogawski M.A., and Porter R.J. Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds. Pharmacol Rev 42 (1990) 223-286
50. Danielsson B.R., Landsdell K., Patmore L., and Tomson T. Phenytoin and phenobarbital inhibit human HERG potassium channels. Epilepsy Res 55 (2003) 147-157
51. Tomson T., and Kennebäck G. Arrhythmia, heart rate variability and antiepileptic drugs. Epilepsia 38 (1997) S48-S51
52. Barron S.A. Cardiac arrhythmias after small iv dose of phenytoin. N Engl J Med 295 (1976) 678
53. Nilsson L., Farahmand B.Y., Persson P.G., Thiblin I., and Tomson T. Risk factors for sudden unexpected death in epilepsy: a case-control study. Lancet 353 (1999) 888-893
54. Danielsson B.R., Azarbayjani F., Skold A.C., and Webster W.S. Initiation of phenytoin teratogenesis: pharmacologically induced embryonic bradycardia and arrhythmia resulting in hypoxia and possible free radical damage at reoxygenation. Teratology 56 (1997) 271-281
55. + channels resulting in hypoxia-reoxygenation damage. Teratology 63 (2001) 152-160
56. Azarbayjani F., and Danielsson B.R. Pharmacologically induced embryonic dysrhythmia and episodes of hypoxia followed by reoxygenation: a common teratogenic mechanism for antiepileptic drugs?. Teratology 57 (1998) 117-126
57. Hanson J.W., and Smith D.W. The fetal hydantoin syndrome. J Pediatr 87 (1975) 285-290
58. Finnell R.H., and Dansky L.V. Parental epilepsy, anticonvulsant drugs and reproductive outcome: epidemiologic and experimental findings spanning three decades; 1: animal studies. Reprod Toxicol 5 (1991) 281-299
59. Brown K.S., Hetzel S.C., Harne L.C., and Long S. Blebs and hematomas in the lips of CL/Fr and A/J mice. J Craniofac Genet Dev Biol Suppl 1 (1985) 313-322
60. Mercier-Parot L., and Tuchmann-Duplessis H. The dysmorphogenic potential of phenytoin: experimental observations. Drugs 8 (1974) 340-353
61. Danielson M.K., Danielsson B.R., Marchner H., Lundin M., Rundqvist E., and Reiland S. Histopathological and hemodynamic studies supporting hypoxia and vascular disruption as explanation to phenytoin teratogenicity. Teratology 46 (1992) 485-497
62. Danielsson B.R., Danielson M., Reiland S., Rundqvist E., Dencker L., and Regard C.G. Histological and in vitro studies supporting decreased uteroplacental blood flow as explanation for digital defects after administration of vasodilators. Teratology 41 (1990) 185-193
63. Danielsson B.R., Danielson M., Rundqvist E., and Reiland S. Identical phalangeal defects induced by phenytoin and nifedipine suggest fetal hypoxia and vascular disruption behind phenytoin teratogenicity. Teratology 45 (1992) 247-258
64. Danielsson B.R., Reiland S., Rundqvist E., and Danielson M. Digital defects induced by vasodilating agents: relationship to reduction in uteroplacental blood flow. Teratology 40 (1989) 351-358
65. Danielsson B., Skold A.C., Azarbayjani F., Ohman I., and Webster W. Pharmacokinetic data support pharmacologically induced embryonic dysrhythmia as explanation to Fetal Hydantoin Syndrome in rats. Toxicol Appl Pharmacol 163 (2000) 164-175
66. Danielsson B.R., Johansson A., Danielsson C., Azarbayjani F., Blomgren B., and Skold A.C. Phenytoin teratogenicity: hypoxia marker and effects on embryonic heart rhythm suggest an hERG-related mechanism. Birth Defects Res A Clin Mol Teratol 73 (2005) 146-153
67. Tiboni G.M., Bucciarelli T., Amicarelli F., et al. Spatial distribution of glutathione, glutathione-related and antioxidant enzymes in cultured mouse embryos. Arch Toxicol 72 (1997) 38-44
68. Mover H., and Ar A. Antioxidant enzymatic activity in embryos and placenta of rats chronically exposed to hypoxia and hyperoxia. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 117 (1997) 151-157
69. Winn L.M., and Wells P.G. Phenytoin-initiated DNA oxidation in murine embryo culture, and embryo protection by the antioxidative enzymes superoxide dismutase and catalase: evidence for reactive oxygen species-mediated DNA oxidation in the molecular mechanism of phenytoin teratogenicity. Mol Pharmacol 48 (1995) 112-120
70. Yu W.K., and Wells P.G. Evidence for lipoxygenase-catalyzed bioactivation of phenytoin to a teratogenic reactive intermediate: in vitro studies using linoleic acid-dependent soybean lipoxygenase, and in vivo studies using pregnant CD-1 mice. Toxicol Appl Pharmacol 131 (1995) 1-12
71. Dansky L.V., and Finnell R.H. Parental epilepsy, anticonvulsant drugs and reproductive outcome: epidemiologic and experimental findings spanning three decades; 2: human studies. Reprod Toxicol 5 (1991) 301-335
72. Azarbayjani F., Borg L.A., and Danielsson B.R. Increased susceptibility to phenytoin teratogenicity: excessive generation of reactive oxygen species or impaired antioxidant defense?. Basic Clin Pharmacol Toxicol 99 (2006) 305-311
73. Azarbayjani F., and Danielsson B.R. Embryonic arrhythmia by inhibition of hERG channels: a common hypoxia-related teratogenic mechanism for antiepileptic drugs?. Epilepsia 43 (2002) 457-468
74. Skold A.C., Danielsson C., Linder B., and Danielsson B.R. Teratogenicity of the I(Kr)-blocker cisapride: relation to embryonic cardiac arrhythmia. Reprod Toxicol 16 (2002) 333-342
75. Taglialatela M., Castaldo P., Pannaccione A., et al. Cardiac ion channels and antihistamines: possible mechanisms of cardiotoxicity. Clin Exp Allergy 29 Suppl. 3 (1999) 182-189
76. Jaffee O.C. The development of the arterial outflow tract in the chick embryo heart. Anat Rec 158 (1967) 35-42
77. Sweeney L.J., Clark E.B., and Rosenquist G.C. Aortic arch anomalies in experimentally prodiced left heart hypoplasia. Pediatr Res 13 (1979) 487-1487
78. Rajala G.M., Kuhlmann R.S., and Kolesari G.L. The role of dysrhythmic heart function during cardiovascular teratogenesis in epinephrine-treated chick embryos. Teratology 30 (1984) 385-392
79. Gilbert E.F., Bruyere Jr. H.J., Ishikawa S., Foulke L.M., and Heimann S.R. Role of decreased cardiac output in isoproterenol-induced cardiovascular teratogenesis in chick embryos. Teratology 21 (1980) 299-307
80. Kirby M.L. Cardiac morphogenesis-recent research advances. Pediatr Res 21 (1987) 219-224
81. Guideline on risk assessment of medicinal products on human reproduction and lactation: from data to labelling. 2006 (EMEA/CHMP/203927/2005).
82. Curran M.E., Splawski I., Timothy K.W., Vincent G.M., Green E.D., and Keating M.T. A molecular basis for cardiac arrhythmia: hERG mutations cause long QT syndrome. Cell 80 (1995) 795-803
83. Gaily E. Development and growth in children of epileptic mothers. A prospective controlled study (1990), Yliopistopaino University of Helsinki, Helsinki
84. Danielsson B.R., and Webster W.S. Cardiovascular active drugs. In: Kavlock R.J., and Daston G. (Eds). Drug toxicity in embryonic development II; advances in understanding mechanisms of birth defects: mechanistic understanding of human developmental toxicants (1997), Springer, Berlin 161-190
85. Wells P.G., and Harbison R.D. Significance of the phenytoin reactive arene oxide intermediate, its oxepin tautomer, and clinical factors modifying their roles in phenytoin-induced teratology. In: Hassell T.M., Johnston M.C., and Dudley K.H. (Eds). Phenytoin-induced teratology and gingival pathology (1980), Raven Press, New York 35-40
86. Tiboni G.M., Iammarrone E., Giampietro F., Lamonaca D., Bellati U., and Di Ilio C. Teratological interaction between the bis-triazole antifungal agent fluconazole and the anticonvulsant drug phenytoin. Teratology 59 (1999) 81-87
87. Wells P.G. Physiological and environmental determinants of phenytoin teratogenicity: relation to glutathione homeostasis, and potentiation by acetaminophen. Prog Clin Biol Res 135 (1983) 367-371
88. Azarbayjani F., and Danielsson B.R. Exaggerated embryonic bradyarrhythmia after exposure to two or more antiepileptic drugs compared to mono exposure. Teratology 58 (1998) 31A
89. Lindhout D. Antiepileptic drugs-clinical results and mechanisms. In: Sundwall A., Danielsson B.R., Hagberg O., Lindgren E., Sjöberg P., and Viktor A. (Eds). Developmental toxicology-preclinical and clinical data in retrospect (1993), Tryckgruppen, Stockholm 111-121
90. Lindhout D., Meinardi H., and Barth P.G. Hazards of fetal exposure do drug combinations. In: Janz D., Dam M., Richens A., Bossi L., and Helge H. (Eds). Epilepsy, pregnancy and the child. 2nd ed. (1982), Raven Press, New York 275-281
91. Karlsson M, Danielsson BR, Nilsson M, Danielsson C, Webster WS. New proposals for testing drugs with IKr blocking activity to determine their teratogenic potential. Curr Pharm Des 2007 (In press).